Report of the OECI Accreditation and Designation Programme 26 May 2021 – General Assembly Simon Oberst, Chair of the A&D Board What is the OECI Accreditation and Designation Programme aiming to achieve? • To drive quality improvements for patients • To provide an independent and objective external quality assessment of Centres • To provide quality standards which are ambitious in terms of excellence • To provide pan-European standards which can be applied in any European country and beyond 2 What are the advantages of an OECI accreditation? . It is the only Europe-wide institutional accreditation which covers both cancer care and research . The Review produces a high quality Improvement Plan (with clear identification of opportunities and a plan to fix them) . There is a real engagement by all disciplines and all levels of staff . The gathering of the data and the self assessment by all departments is a benefit in itself (for self monitoring and learning) . The programme reached 52 European centres in 2021, many more in the pipeline 13 How does the A&D Programme add value for patients? • There are large sections of the questionnaires around patient satisfaction and involvement in the centre • The peer review is part of a toolbox to improve outcomes for patients • It disseminates research and implementation of best practice • The process spurs collaboration and the development of networks 4 The A&D Board 2020/21 • Simon Oberst, Cambridge, Chair • Wim van Harten, Arnhem, The Netherlands • Paolo de Paoli, ACC network, Italy • Peter Nagy, Budapest • Jean-Benoît Burrion, Brussels • Gunnar Sæter, Oslo • Eva Gustafsson, Stockholm • Mef Nilbert, Copenhagen • Jozsef Lovey, Budapest (chair of Accreditation Committee) The Accreditation Committee 2020/21 • Jozsef Lovey, Budapest (Chair)(Previously Gunnar Saeter – whom, thanks!) • Henk Hummel, Groningen • Irène Philip, Lyon • Marek Svoboda, Brno • Mari-Leen Pärn, Estonia • Jorrit Enserink, Oslo • Francesco Monetti (until January 2021 – many thanks) • Rui Silva, Coimbra (until January 2021 – many thanks) Many thanks to the support from: • The IKNL team: Harriët Blaauwgeers; Willien Westerhuis; Annemiek Kwast (till Nov 2020); Jolanda van Hoeve; Heidi van Doorne; Sylvia Blommestein. • At Cambridge: Kelly O’Reilly • At Genova (SOS Europe): Claudio Lombardo; Giorgia Pesce; Daniela Garbarino; Patrizia Sommella and Roxanna Plesoianu 52 centres now in the programme Accredited - Cancer Centre - 16 Accredited - Comprehensive Cancer Centre - 24 Newly in the accreditation process - 12 Centres with a Peer Review in 2021 • Istituto Tumori, Milan, Italy 2nd • CROB Basilicata, Italy 2nd • Kuopio University Hospital, Finland • Skäne University Hospital, Lund, Sweden • Sahlgrenska University Hospital, Gothenburg, Sweden • Vejle Cancer Centre, Denmark 2nd • Beaumont Cancer Centre, Dublin • Tartu Cancer Centre, Estonia 2nd • Candiolo Cancer Institute, Turin, Italy • Groningen University Hospital, The Netherlands • Ljubljana Cancer Centre, Slovenia • AP-HP CARPEM Paris, France Network • ATOP network - Toulouse The programme is growing across Europe and beyond • Growth in applications across France to the majority of Cancer Centres • Substantial growth in the Nordic Countries – complete in Finland • New centres in Spain • Nearly complete coverage in Italy and Portugal • Interest from Poland, Denmark, Chile, Colombia, Vietnam, China, Dublin, Latvia • Our total cohort of centres produce more than 12,400 research papers annually, have annual research budgets of more than €1 billion, and have treated more than 1 million new cancer patients since their accreditations Important developments • Great success with virtual and semi-virtual peer reviews (9) • More than 65 trained auditors in many different disciplines. • New standards for Cancer Networks/Infrastructures (piloted in France in March 2021) – shortly to be published • Participating in iPAAC WP7 and WP10 • Significant input into European Commission and Cancer Mission Board re the planning of Cancer Mission and Beating Cancer Plan. • Excellent Practices project to disseminate – 26 practices across Europe – for Summer 2021 • Steps to improve our Communications • A&D Standards going through ISQua re-accreditation • Manual 3.0 is now operational Papers published and in preparation Published 1. 100 European core quality standards for cancer care and research centres. Oberst et al, Lancet Oncology, August 2020 2. Analysing the attributes of Comprehensive Cancer Centres and Cancer Centres across Europe to identify key hallmarks. Kehrloesser et al, Molecular Oncology, March 2021 In preparation 1. Evaluating Comprehensive Cancer Networks; a new tool to drive up quality – featuring OECI’s new European Standards 2. What is a roadmap to creating successful CCCs out of University Medical Centres? – especially relevant to the EU Cancer Mission objective to create Comprehensive Cancer Infrastructures in every Member State. EU Cancer Mission and Europe’s Beating Cancer Plan • Recommendation 10 of the Cancer Mission Board: Set up a Network of Comprehensive Cancer Infrastructures within and across all EU member states to improve the quality of research and care. • EBCP Flagship 5 to set up a EU Network of National CCCs by 2025 – to reach 90% of eligible patients by 2030 – reinforces that purpose. Joint aims . Diminish inequalities of access to treatment and access to clinical trials . Harmonise standards of care and research using accreditation standards EU countries with almost full coverage of accredited centres: . Italy . France . Germany . Finland . Portugal EU countries with no accredited centres yet: . Slovakia . Greece . Croatia . Bulgaria . Malta . Cyprus . Latvia (applying) . Poland (applying) . Slovenia (in progress) . Luxembourg (in progress) 14 The emphasis should be on formation and improvement of centres/networks, prior to accreditation • OECI has expertise to consult at a local infrastructure level to get there…. Advice on governance and organisation (centres and networks) Advice on multidisciplinarity (MDTs+researchers) Consultancy around clinical trials organisation and recruitment Consultancy on data, samples, standardisation Tracking outcomes and treatment optimisation Knowledge exchange programmes Sharing excellent practices • Accreditation is then helpful as part of an improvement process to address Innovation, Implementation, Inequalities. Thank you for your attention 17 BIOBANKING AND MOLECULAR PATHOBIOLOGY WG Biobanking and Molecular Pathobiology W.G. Activities developed in 2020-2021 Chair: Giorgio Stanta 26th May 2021 BIOBANKING AND MOLECULAR PATHOBIOLOGY WG Activities: 1-Molecular analysis reproducibility: pre-analytical conditions -SPIDIA4P project: CEN /TC 140/WG3 Technical Specifications >>> translated into 15189 ISO International Standards 2-Molecular analysis reproducibility: standardized methods -Instand-NGS project: project for evaluation of NGS products on the market 3-Heterogeneity -HERCULES project: single cell heterogeneity in HGSOC 4-Clinical Research -European Commission Initiative on Breast Cancer (ECIBC) 5-Meetings and Courses -EACR/OECI Cancer Molecular Pathology Course (Virtual 23-24 March 2021) -Oncology Day 2021: Mol diagn and clin res reproducibility: a European Mission 6-Teaching activities -European Molecular Pathology Master BIOBANKING AND MOLECULAR PATHOBIOLOGY WG European Molecular Pathology Master #The master was chosen as a modality to standardize diagnostic molecular pathology in Europe. # The steering committee of the master (people in charge of the different country molecular pathology initiatives) can modify the program continuously allowing the diagnostic molecular pathology to be always updated. #The program is based on the already developed experience of the French diploma and the evaluation of it based on other existing courses and diplomas in Europe such the ones in Netherlands and Germany. #As today diagnostic molecular pathology is directly connected to diagnostics and treatment, the standardization of the analyses is a basic requirement to make them reproducible and exchangeable among European health institutions. BIOBANKING AND MOLECULAR PATHOBIOLOGY WG Collaboration of BBMP WG: Other Organizations: #Collaboration with BBMRI-ERIC and ISBER for biobanking #University of Nice: Biobanking Master #ESP Molecular Pathology WG #Collaboration with CEN (European Committee for Standardization) #EACR Cancer Molecular Pathology Course (Virtual 23-24 March 2021) #European Commission Initiative on Breast Cancer (ECIBC) #UEMS for the development of European Molecular Pathology Master European Projects: #HERCULES project for single cell heterogeneity in HGSOC #SPIDIA4P Pre-analytical condition of clinical material (CEN, BBMRI-ERIC, ISO) #Instand-NGS project for evaluation of NGS products on the market Working Group Health Economics (2020-2021) • Board selected • 3 Board meetings, • Lionel Perrier (Fr) • 2 Working group meetings with • Davide Galegati (It) ±30 participants. • Edit Porcneczy (Hu) • Scientific session in Annual • Michael Schlander (Ge) replaced Raul Kiivet (Est) Scientific Meeting 16/6 and • Marien van der Meer (NL) board • 3rd Working Group meeting representative 17/6 planned. • Valesca Retel (NL) Coordinator • WvH (NL) Chair. Working Group Health Economics • Support and Liaison with European Fair Pricing Network (EFPN) (exposure in Eu press, Eu parliament and with Commissioners). • Participation of Chair in EACS working group on Health Economics (paper in preparation) • (SUB)Task Force on Methods